We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+91.23%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$735M
AUM Growth
+$18.1M
Cap. Flow
+$54.1M
Cap. Flow %
7.36%
Top 10 Hldgs %
42.08%
Holding
212
New
67
Increased
34
Reduced
65
Closed
41

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$11.6M
2
TGTX icon
TG Therapeutics
TGTX
+$8.36M
3
BPMC
Blueprint Medicines
BPMC
+$7.73M
4
FBRX icon
Forte Biosciences
FBRX
+$7.25M
5
VIR icon
Vir Biotechnology
VIR
+$7.08M

Top Sells

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$19.2M
2
ONC
BeOne Medicines Ltd
ONC
+$18M
3
SLNO
Soleno Therapeutics
SLNO
+$11.5M
4
RCUS icon
Arcus Biosciences
RCUS
+$5.97M
5
TECX
Tectonic Therapeutic
TECX
+$5.28M

Sector Composition

Rank Sector Weight
1 Healthcare 47.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLN
201
Silence Therapeutics
SLN
$495M
– –
-587,343
Closed -$3.37M
SLNO
202
CALL
DELISTED
Soleno Therapeutics
SLNO
– –
-110,000
Closed -$5.55M
SLNO
203
DELISTED
Soleno Therapeutics
SLNO
– –
-221,437
Closed -$11.5M
SRRK icon
204
PUT
Scholar Rock
SRRK
$5.67B
– –
-202,100
Closed -$1.62M
SWTX
205
CALL
DELISTED
SpringWorks Therapeutics
SWTX
– –
-43,800
Closed -$1.4M
VRTX icon
206
CALL
Vertex Pharmaceuticals
VRTX
$121B
– –
-100,000
Closed -$46.5M
VRTX icon
207
PUT
Vertex Pharmaceuticals
VRTX
$121B
– –
-100,000
Closed -$46.5M
WVE icon
208
Wave Life Sciences
WVE
$1.09B
– –
-544,265
Closed -$4.46M
ANRO icon
209
CALL
Alto Neuroscience
ANRO
$1.05B
– –
-431,000
Closed -$4.93M
ANRO icon
210
PUT
Alto Neuroscience
ANRO
$1.05B
– –
-450,000
Closed -$5.15M
ONC
211
BeOne Medicines Ltd
ONC
$32.8B
– –
-88,167
Closed -$18M
MRNS
212
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-706,154
Closed -$1.24M
5 6 7 8
9

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Ikarian Capital held 212 positions worth $735M, up 2.5% from $717M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ikarian Capital deployed $54.1M of net new capital in Q4 2024, opening 67 new positions and adding to 34 existing holdings. Its largest new stake was Scholar Rock: 357,185 shares worth $15.4M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 45% a quarter earlier.

On the sell side, the largest reduction was Tarsus Pharmaceuticals, an estimated $19.2M trimmed.

  • Ikarian Capital's largest Q4 2024 buy was Scholar Rock: 357,185 shares worth $15.4M.
  • Ikarian Capital added most to Blueprint Medicines in Q4 2024, an estimated $7.73M increase.
  • Ikarian Capital's biggest Q4 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $19.2M.
  • Ikarian Capital fully exited BeOne Medicines Ltd in Q4 2024, selling an estimated $18M.
  • Ikarian Capital's ten largest holdings make up 42% of its $735M portfolio in Q4 2024.
  • Ikarian Capital opened 67 new positions and closed 41 in Q4 2024.
  • Ikarian Capital's portfolio value rose 2.5% quarter-over-quarter to $735M.

Based on Ikarian Capital's 13F filing for Q4 2024, filed 14 Feb 2025.